The Role of Botulinum Toxin for Masseter Muscle Hypertrophy: A Comprehensive Review
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10494875" target="_blank" >RIV/00064165:_____/25:10494875 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10494875 RIV/00216208:11130/25:10494875
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=LZIdGk4Hn" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=LZIdGk4Hn</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/toxins17020091" target="_blank" >10.3390/toxins17020091</a>
Alternative languages
Result language
angličtina
Original language name
The Role of Botulinum Toxin for Masseter Muscle Hypertrophy: A Comprehensive Review
Original language description
Masticatory muscle hypertrophy (MMH) is a rare clinical phenomenon of uncertain etiology, characterized by a soft swelling near the angle of the jaw. This abnormal enlargement of the masseter muscle can alter the facial profile, leading to aesthetic concerns. Moreover, MMH may also have significant functional repercussions, including pain in the masseter region, often associated with temporomandibular disorders, fatigue, and discomfort during mastication. Non-conservative approaches offer an effective and minimally invasive solution by inducing localized muscle relaxation and reducing hypertrophy. Botulinum neurotoxin type A (BoNT/A) represents a therapeutic option for managing MMH, considering that injections can effectively reduce the masseter muscle volume, improving both facial aesthetics and related symptoms. Currently, the standard non-surgical management of MMH is BoNT/A injections, although consensus on the average dosage has not been definitely reached; on the other hand, there are data available in the literature about the injection technique of BoNT/A for lower face contouring. Therefore, the present comprehensive review aimed at exploring in detail the role of BoNT/A in the treatment of masseter muscle hypertrophy, describing its mechanism of action, the administration protocols, the clinical effects, and any side effects.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30306 - Sport and fitness sciences
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Toxins
ISSN
2072-6651
e-ISSN
2072-6651
Volume of the periodical
17
Issue of the periodical within the volume
2
Country of publishing house
CH - SWITZERLAND
Number of pages
19
Pages from-to
91
UT code for WoS article
001429475100001
EID of the result in the Scopus database
2-s2.0-85219195606